Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524705 | 1.00 | CA1 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL15524706 | 1.00 | CA1 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL18027565 | 0.87 | CA1 (0.41) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL16616685 | 0.87 | CA1 (0.41) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL16820724 | 0.87 | CA1 (0.41) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL716556 | 0.85 | PLA2G10 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL7226223 | 0.83 | TDP1 (0.42) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL18413379 | 0.83 | PLA2G10 (0.36) | CA1TSHRKMT2APLA2G10PLA2G2A | |
| SCHEMBL7218954 | 0.82 | CA1 (0.38) | CA1TSHRCA2CA7CA9 | |
| SCHEMBL2569081 | 0.82 | CA1 (0.44) | CA1TSHRCA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244411-A1 | TAU IMAGING PROBE | CLINO LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | RESOLVYX PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | SCHWARTZ C ERIC | 2011-10-06 | — | — | US | disclosed |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | ALOX5, ALOX15B, ALOX12 | CA1 4716/4885TSHR 3738/4885CA2 4428/4885 |
| US-20110190242-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | ALOX15B, ALOX12, ALOX15 | CA1 3959/4885TSHR 4290/4885CA2 3888/4885 |
| US-20120122816-A1 | COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION | ALOX5, ALOX15B, ALOX12 | CA1 1608/4885TSHR 4636/4885CA2 3799/4885 |
| US-20160244411-A1 | TAU IMAGING PROBE | MAPT, PSEN1, PSEN2 | CA1 250/4885TSHR 2913/4885CA2 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.